Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.
Zhou X, Hofmann A, Engel B, Vogt C, Nerreter S, Tamamushi Y, Schmitt F, Leberzammer M, Stanojkovska E, Truger M, Xiao X, Riedhammer C, Steinhardt MJ, John M, Mersi J, Han S, Munawar U, Waldschmidt JM, Haferlach C, Einsele H, Rasche L, Kortüm KM. Zhou X, et al. Among authors: xiao x. Hemasphere. 2025 Jan 23;9(1):e70078. doi: 10.1002/hem3.70078. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39850647 Free PMC article.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt MJ, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez MM, Munawar U, Riedel A, Han S, Maurits E, Overkleeft HS, Florea B, Einsele H, Kortüm KM, Driessen C, Besse L, Rasche L. Zhou X, et al. Among authors: xiao x. Haematologica. 2023 Jun 1;108(6):1628-1639. doi: 10.3324/haematol.2022.282225. Haematologica. 2023. PMID: 36727403 Free PMC article.
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.
Steinhardt MJ, Truger M, Bittrich M, Zhou X, Noderer J, Riedhammer C, Xiao X, Gawlas S, Weis P, Eisele F, Haferlach C, Mersi J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM. Steinhardt MJ, et al. Among authors: xiao x. Haematologica. 2024 Mar 1;109(3):979-981. doi: 10.3324/haematol.2023.283472. Haematologica. 2024. PMID: 37794827 Free PMC article. No abstract available.
Bispecific Antibodies in the Treatment of Multiple Myeloma.
Zhou X, Xiao X, Kortuem KM, Einsele H. Zhou X, et al. Among authors: xiao x. Hematol Oncol Clin North Am. 2024 Apr;38(2):361-381. doi: 10.1016/j.hoc.2023.12.003. Epub 2024 Jan 9. Hematol Oncol Clin North Am. 2024. PMID: 38199897 Review.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L. Zhou X, et al. Among authors: xiao x. Br J Haematol. 2024 Sep;205(3):999-1010. doi: 10.1111/bjh.19515. Epub 2024 May 8. Br J Haematol. 2024. PMID: 38719214
12,513 results
You have reached the last available page of results. Please see the User Guide for more information.